Infectious Diseases Unit, the Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
Infectious Diseases Group and.
Am J Respir Crit Care Med. 2022 Apr 1;205(7):830-841. doi: 10.1164/rccm.202108-1892OC.
Scar formation following bacillus Calmette-Guérin (BCG) vaccination has been associated with lower all-cause mortality; the relation between scar and mycobacteria-specific protection against tuberculosis is debated. To evaluate the association between BCG skin reaction and mycobacteria-specific immune responses. A analysis was done among 214 infants in Australia randomized to vaccination with one of three BCG vaccine strains (BCG-Denmark, BCG-Japan, or BCG-Russia) given at birth or BCG-Denmark given at 2 months of age. BCG skin reaction size and characteristics 10 weeks after vaccination were related to the mycobacteria-specific immune responses measured in stimulated whole blood. The size and characteristics of the skin reaction correlated positively with immune responses, even after adjusting for BCG vaccine strain and age at vaccination. Specifically, the reaction size and characteristics correlated with the proportion of mycobacteria-specific polyfunctional CD4 T cells after stimulation with BCG and PPD and, to a lesser extent, after stimulation with or . A similar correlation was observed with concentrations of IFN-γ, IL-2, tumor necrosis factor, and IL-13 in the supernatant after stimulation with BCG, PPD, and and to some degree for the proportions of mycobacteria-specific polyfunctional CD8 T cells and CD107 cytotoxic cells. BCG skin reaction correlated with the magnitude of mycobacteria-specific T-cell responses. As T-cell responses play a key role in defense against mycobacteria, the relationship between BCG scar formation and protection against tuberculosis should be revisited. This may also extend to the need for BCG revaccination in scar-negative individuals.Clinical trial registered with www.australianclinicaltrials.gov.au/clinical-trial-registries (ACTRN12608000227392).
卡介苗(BCG)接种后瘢痕形成与全因死亡率降低有关;瘢痕与结核分枝杆菌特异性保护之间的关系存在争议。为评估 BCG 皮肤反应与分枝杆菌特异性免疫反应之间的关系。在澳大利亚,对 214 名婴儿进行了一项 分析,这些婴儿随机接种三种 BCG 疫苗菌株(BCG-丹麦、BCG-日本或 BCG-俄罗斯)中的一种,出生时接种或 BCG-丹麦在 2 个月时接种。接种后 10 周,BCG 皮肤反应大小和特征与刺激全血中测量的分枝杆菌特异性免疫反应相关。皮肤反应的大小和特征与免疫反应呈正相关,即使在调整 BCG 疫苗株和接种年龄后也是如此。具体而言,反应大小和特征与刺激后分枝杆菌特异性多功能 CD4 T 细胞的比例相关,与刺激后 和 的比例相关较小,与刺激后 BCG、PPD 和 上清液中 IFN-γ、IL-2、肿瘤坏死因子和 IL-13 的浓度也存在类似的相关性,在一定程度上也与分枝杆菌特异性多功能 CD8 T 细胞和 CD107 细胞毒性细胞的比例相关。BCG 皮肤反应与分枝杆菌特异性 T 细胞反应的幅度相关。由于 T 细胞反应在防御分枝杆菌方面发挥着关键作用,因此应重新审视 BCG 瘢痕形成与预防结核病之间的关系。这也可能扩展到需要对无瘢痕个体进行 BCG 复种。临床试验在 www.australianclinicaltrials.gov.au/clinical-trial-registries (ACTRN12608000227392) 上注册。